Answer
Fasenra (benralizumab) is indicated as add-on maintenance treatment for adults with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.
Sources for this answer
- Fasenra 30 mg solution for injection in pre filled penAstraZeneca UK Limited · emc · SmPC §4.1 Therapeutic Indications · Version 9Document updated
Sources checked